256 related articles for article (PubMed ID: 25955153)
1. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
Shi Q; Schroeder JA; Kuether EL; Montgomery RR
J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
[TBL] [Abstract][Full Text] [Related]
2. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
3. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
4. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
5. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
Boylan B; Rice AS; De Staercke C; Eyster ME; Yaish HM; Knoll CM; Bean CJ; Miller CH;
J Thromb Haemost; 2015 Jun; 13(6):1036-42. PubMed ID: 25780857
[TBL] [Abstract][Full Text] [Related]
7. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
[TBL] [Abstract][Full Text] [Related]
8. The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.
Chen Y; Schroeder JA; Chen J; Luo X; Baumgartner CK; Montgomery RR; Hu J; Shi Q
Blood; 2016 Mar; 127(10):1346-54. PubMed ID: 26668132
[TBL] [Abstract][Full Text] [Related]
9. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A.
Shi Q; Wilcox DA; Fahs SA; Fang J; Johnson BD; DU LM; Desai D; Montgomery RR
J Thromb Haemost; 2007 Feb; 5(2):352-61. PubMed ID: 17269937
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
[TBL] [Abstract][Full Text] [Related]
11. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
[TBL] [Abstract][Full Text] [Related]
12. Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo.
Shi Q; Kuether EL; Schroeder JA; Perry CL; Fahs SA; Cox Gill J; Montgomery RR
J Thromb Haemost; 2012 Nov; 10(11):2328-37. PubMed ID: 22908929
[TBL] [Abstract][Full Text] [Related]
13. Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice.
Zhang G; Shi Q; Fahs SA; Kuether EL; Walsh CE; Montgomery RR
Blood; 2010 Aug; 116(8):1235-43. PubMed ID: 20445020
[TBL] [Abstract][Full Text] [Related]
14. Platelet and endothelial expression of clotting factors for the treatment of hemophilia.
Montgomery RR; Shi Q
Thromb Res; 2012 May; 129 Suppl 2(Suppl 2):S46-8. PubMed ID: 22421106
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
Shi Q; Wilcox DA; Fahs SA; Weiler H; Wells CW; Cooley BC; Desai D; Morateck PA; Gorski J; Montgomery RR
J Clin Invest; 2006 Jul; 116(7):1974-82. PubMed ID: 16823491
[TBL] [Abstract][Full Text] [Related]
16. Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF.
Shi Q; Wilcox DA; Fahs SA; Kroner PA; Montgomery RR
Mol Genet Metab; 2003 May; 79(1):25-33. PubMed ID: 12765843
[TBL] [Abstract][Full Text] [Related]
17. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.
Damon AL; Scudder LE; Gnatenko DV; Sitaraman V; Hearing P; Jesty J; Bahou WF
Thromb Haemost; 2008 Dec; 100(6):1111-22. PubMed ID: 19132238
[TBL] [Abstract][Full Text] [Related]
18. Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells.
Jing W; Baumgartner CK; Xue F; Schroeder JA; Shi Q
J Thromb Haemost; 2023 Mar; 21(3):488-498. PubMed ID: 36696197
[TBL] [Abstract][Full Text] [Related]
19. Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.
Shi Q; Kuether EL; Chen Y; Schroeder JA; Fahs SA; Montgomery RR
Blood; 2014 Jan; 123(3):395-403. PubMed ID: 24269957
[TBL] [Abstract][Full Text] [Related]
20. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII.
Wilcox DA; Shi Q; Nurden P; Haberichter SL; Rosenberg JB; Johnson BD; Nurden AT; White GC; Montgomery RR
J Thromb Haemost; 2003 Dec; 1(12):2477-89. PubMed ID: 14675082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
